Ground News

News from The Transylvania Times

All of today’s top news stories from The Transylvania Times. Get the full analysis behind how media bias impacts breaking news.

Overall, we’ve indexed 62 stories from The Transylvania Times over the past 3 months.

We’ve assigned a media bias rating of Lean Left to The Transylvania Times. You can read more about our methodology here.

If you want to know if The Transylvania Times is credible or reliable, look no further. We rank The Transylvania Times as High factuality. Find out more about our methodology here.

Information about The Transylvania Times

Where is The Transylvania Times located?The Transylvania Times's Website

Media Bias Ratings

Average Bias Rating:

byMedia Bias/Fact Check

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top The Transylvania Times News

IOC · Beijing

IOC finds Olympic sponsor in China through 2032 to replace Panasonic of Japan

48% Center coverage: 27 sources

See the Story

US Postal Service · Washington

Postal Service Responds to Postal Regulatory Commission's Advisory Opinion on Service Standard Changes

60% Center coverage: 20 sources

WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- The Postal Service today provided a pointed response to the Postal Regulatory Commission's (PRC) recently published Advisory Opinion on the organization's proposed service standard changes: PRC Docket No. N2024-1, captioned "Operational and Service Standards…See the Story

China · China

Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer

57% Center coverage: 19 sources

HONG KONG, Feb. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III clinical trial of ivonescimab in combination with chemotherapy for…See the Story

News from The Transylvania Times